Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Clinical

Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies

Prostate Cancer and Prostatic Diseases volume 28, pages 632–638 (2025)Cite this article

Subjects

Abstract

Background

The prevalence of cardiovascular risk factors and disease is high in patients with newly diagnosed prostate cancer (PC). Survivorship of PC patients is often determined by cardiovascular disease (CVD). Our review synthesizes the most recent literature exploring the dynamics between PC and CVD across the disease trajectory and treatments. We review key ongoing clinical trials in the field and highlight avenues for future study.

Methods

We conducted a comprehensive narrative review of the literature using various search strategies in three databases (PubMed, Web of Science, ClinicalTrials.gov), focusing on literature published between 2000 and 2024.

Results

We discuss the significance of CVD-related mortality in PC, review the risk factors, and highlight potential mechanisms for accelerated CVD in the androgen-deprivation setting. Furthermore, we summarize key literature of CVD and cardiotoxicity for various therapeutic approaches in PC, including orchiectomy, taxane-based chemotherapy, GnRH-axis targets, and next-generation hormonal agents and PARP inhibitors. Lastly, we discuss prevention strategies and the importance of multi-disciplinary care in this setting.

Conclusion

CVD is a major cause of death in men with PC. Various novel therapeutic approaches have been pivotal in improving oncologic outcomes, but emerging data demonstrate a complex interplay between the androgen axis and CVD that is likely affected by modern treatment strategies. Given the prolonged PC survivorship, unraveling non-oncologic related causes of death and investigating prevention strategies are imperative (Fig. 1).

Spectrum of prostate cancer disease states (red) and interventions (yellow) with the potential role for optimization (green) to improve cardiovascular outcomes in the future (blue).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA: A Cancer J Clin. 2021;71:209–49.

    Google Scholar 

  2. Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl J Med. 2023;388:1547–58.

    Article  PubMed  Google Scholar 

  3. Weiner AB, Li EV, Desai AS, Press DJ, Schaeffer EM. Cause of death during prostate cancer survivorship: a contemporary, US population-based analysis. Cancer. 2021;127:2895–904.

    Article  PubMed  Google Scholar 

  4. Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Prim. 2021;7:9.

    Article  PubMed  Google Scholar 

  5. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl J Med. 2022;386:1132–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399:1695–707.

    Article  PubMed  CAS  Google Scholar 

  7. Townsend N, Kazakiewicz D, Lucy Wright F, Timmis A, Huculeci R, Torbica A, et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022;19:133–43.

    Article  PubMed  Google Scholar 

  8. Dahlöf B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol. 2010;105:3A–9A.

    Article  PubMed  Google Scholar 

  9. Ye Y, Zheng Y, Miao Q, Ruan H, Zhang X. Causes of death among prostate cancer patients aged 40 years and older in the United States. Front Oncol. 2022;12:914875.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Häggström C, Stocks T, Ulmert D, Bjørge T, Ulmer H, Hallmans G, et al. Prospective study on metabolic factors and risk of prostate cancer. Cancer. 2012;118:6199–206.

    Article  PubMed  Google Scholar 

  11. Nguyen-Nielsen M, Møller H, Tjønneland A, Borre M. Causes of death in men with prostate cancer: results from the Danish Prostate Cancer Registry (DAPROCAdata). Cancer Epidemiol. 2019;59:249–57.

    Article  PubMed  Google Scholar 

  12. Kjellstadli C, Forster RB, Myklebust TÅ, Bjørge T, Bønaa KH, Helle SI, et al. Cardiovascular outcomes after curative prostate cancer treatment: a population-based cohort study. Front Oncol. 2023;13:1121872.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Luo Z, Chi K, Zhao H, Liu L, Yang W, Luo Z, et al. Cardiovascular mortality by cancer risk stratification in patients with localized prostate cancer: a SEER-based study. Front Cardiovasc Med. 2023;10:1130691.

  14. D’Agostino RB Sr, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: insights from Framingham. Glob Heart. 2013;8:11–23.

    Article  PubMed  Google Scholar 

  15. Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D, Ho E, et al. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology. 2013;1:583–9.

    Article  PubMed  CAS  Google Scholar 

  16. Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203:1109–16.

    Article  PubMed  Google Scholar 

  17. Klimis H, Pinthus JH, Aghel N, Duceppe E, Fradet V, Brown I, et al. The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis. JACC CardioOncol. 2023;5:70–81.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Sun L, Parikh RB, Hubbard RA, Cashy J, Takvorian SU, Vaughn DJ, et al. Assessment and management of cardiovascular risk factors among US Veterans with prostate cancer. JAMA Netw Open. 2021;4:e210070.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontology: Ser A. 2001;56:M146–57.

    CAS  Google Scholar 

  20. Kojima G, Iliffe S, Walters K. Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age Ageing. 2018;47:193–200.

    Article  PubMed  Google Scholar 

  21. Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol. 2009;6:712–22.

    Article  PubMed  Google Scholar 

  22. Wang J-Y, Wang C-Y, Juang S-Y, Huang K-Y, Chou P, Chen C-W, et al. Low socioeconomic status increases short-term mortality of acute myocardial infarction despite universal health coverage. Int J Cardiol. 2014;172:82–7.

    Article  PubMed  Google Scholar 

  23. Hassen HY, Bastiaens H, Van Royen K, Abrams S. Socioeconomic and behavioral determinants of cardiovascular diseases among older adults in Belgium and France: a longitudinal analysis from the SHARE study. PLoS ONE. 2020;15:e0243422.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Rosengren A, Smyth A, Rangarajan S, Ramasundarahettige C, Bangdiwala SI, AlHabib KF, et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. Lancet Glob Health. 2019;7:e748–60.

    Article  PubMed  Google Scholar 

  25. Stabellini N, Cullen J, Bittencourt MS, Moore JX, Cao L, Weintraub NL, et al. Allostatic load and cardiovascular outcomes in males with prostate cancer. JNCI Cancer Spectr. 2023;7:pkad005.

  26. Björklund J, Stattin P, Rönmark E, Aly M, Akre O. The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study. BJU Int. 2022;129:318–24.

    Article  PubMed  Google Scholar 

  27. Ayoub CH, El-Asmar JM, Abou Heidar NF, Najm N, Nasrallah AA, Tamim H, et al. A novel radical prostatectomy specific index (PSI) for the prediction of major cardiovascular events following surgery. Int Urol Nephrol. 2022;54:3069–78.

    Article  PubMed  Google Scholar 

  28. Wallis CJ, Mahar AL, Satkunasivam R, Herschorn S, Kodama RT, Lee Y, et al. Cardiovascular and skeletal-related events following localized prostate cancer treatment: role of surgery, radiotherapy, and androgen deprivation. Urology. 2016;97:145–52.

    Article  PubMed  Google Scholar 

  29. Kohutek ZA, Weg ES, Pei X, Shi W, Zhang Z, Kollmeier MA, et al. Long-term impact of androgen-deprivation therapy on cardiovascular morbidity after radiotherapy for clinically localized prostate cancer. Urology. 2016;87:146–52.

    Article  PubMed  Google Scholar 

  30. Melloni C, Roe MT. Androgen deprivation therapy and cardiovascular disease. Urol Oncol. 2020;38:45–52.

    Article  PubMed  CAS  Google Scholar 

  31. Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8:118–29.

    Article  PubMed  CAS  Google Scholar 

  32. Swaby J, Aggarwal A, Batra A, Jain A, Seth L, Stabellini N, et al. Association of androgen deprivation therapy with metabolic disease in prostate cancer patients: an updated meta-analysis. Clin Genitourin Cancer. 2023;21:e182–9.

    Article  PubMed  Google Scholar 

  33. Dragomir A, Touma N, Hu J, Perreault S, Aprikian AG. Androgen deprivation therapy and risk of cardiovascular disease in patients with prostate cancer based on existence of cardiovascular risk. J Natl Compr Canc Netw. 2023;21:163–71.

    Article  PubMed  CAS  Google Scholar 

  34. Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation. 2010;121:833–40.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Wilcox C, Kautto A, Steigler A, Denham JW. Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term. Oncology. 2012;82:56–8.

    Article  PubMed  CAS  Google Scholar 

  36. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599–603.

    Article  PubMed  CAS  Google Scholar 

  37. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63:742–5.

    Article  PubMed  Google Scholar 

  38. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112:2188–94.

    Article  PubMed  CAS  Google Scholar 

  39. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol. 2011;74:377–83.

    Article  CAS  Google Scholar 

  40. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305–8.

    Article  PubMed  CAS  Google Scholar 

  41. Chan JSK, Lee YHA, Liu K, Hui JMH, Dee EC, Ng K, et al. HbA1c variability and cardiovascular events in patients with prostate cancer receiving androgen deprivation therapy. Eur Urol Open Sci. 2023;47:3–11.

    Article  PubMed  Google Scholar 

  42. Forster RB, Engeland A, Kvåle R, Hjellvik V, Bjørge T. Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer. Int J Cancer. 2022;151:1109–19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Tsai HK, D’Amico AV, Sadetsky N, Chen M-H, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. JNCI: J Natl Cancer Inst. 2007;99:1516–24.

    Article  PubMed  Google Scholar 

  44. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS ONE. 2014;9:e107516.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Nguyen PL, Je Y, Schutz FAB, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359–66.

    Article  PubMed  CAS  Google Scholar 

  46. Bonsu J, Charles L, Guha A, Awan F, Woyach J, Yildiz V, et al. Representation of patients with cardiovascular disease in pivotal cancer clinical trials. Circulation. 2019;139:2594–6.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Nelson Adam J, Lopes Renato D, Hong H, Hua K, Slovin S, Tan S, et al. Cardiovascular Effects of GnRH antagonists compared with agonists in prostate cancer. JACC: CardioOncol. 2023;5:613–24.

    PubMed  CAS  Google Scholar 

  48. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al. Cardiovascular safety of Degarelix Versus Leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE Randomized Trial. Circulation. 2021;144:1295–307.

    Article  PubMed  PubMed Central  Google Scholar 

  49. GmbH SPS. Randomized study to evaluate MACE in patients with prostate cancer treated with Relugolix or Leuprolide Acetate: ClinicalTrials.gov; 2024. https://clinicaltrials.gov/study/NCT05605964.

  50. Zhang KW, Reimers MA, Calaway AC, Fradley MG, Ponsky L, Garcia JA, et al. Cardiovascular events in men with prostate cancer receiving hormone therapy: an analysis of the FDA Adverse Event Reporting System (FAERS). J Urol. 2021;206:613–22.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Cone EB, Marchese M, Reese SW, Sun M, Nabi J, Kilbridge K, et al. Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists. BJU Int. 2020;126:9–10.

    Article  PubMed  CAS  Google Scholar 

  52. Pinthus D. Cardiovascular risk in ADT recipients: does the type of ADT matter? Prostate Cancer Prostatic Dis. 2024;27:1–3.

  53. Kan WC, Hsieh KL, Chen YC, Ho CH, Hong CS, Chiang CY, et al. Comparison of Surgical or medical castration-related cardiotoxicity in patients with prostate cancer. J Urol. 2022;207:841–50.

    Article  PubMed  Google Scholar 

  54. Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS, et al. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl. 2015;17:493–6.

    Article  PubMed  CAS  Google Scholar 

  55. Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65:704–9.

    Article  PubMed  CAS  Google Scholar 

  56. Rajwa P, Pradere B, Gandaglia G, van den Bergh RCN, Tsaur I, Shim SR, et al. Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: a systematic review and meta-analysis. Eur Urol. 2022;82:82–96.

    Article  PubMed  CAS  Google Scholar 

  57. Heath EI, Dyson GE, Cackowski FC, Hafron J, Powell I. Treatment intensification patterns and utilization in patients with metastatic castration-sensitive prostate cancer. Clin Genitourin Cancer. 2022;20:524–32.

    Article  PubMed  Google Scholar 

  58. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Lowrance WDR, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline. J Urol. 2023;209:1082–90.

    Article  PubMed  Google Scholar 

  60. Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with Enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40:1616–22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Chi KN, Chowdhury S, Bjartell A, Chung BH, Gomes AJPdS, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, Phase III TITAN study. J Clin Oncol. 2021;39:2294–303.

    Article  PubMed  CAS  Google Scholar 

  62. Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide Plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS Trial. J Clin Oncol. 2023;41:3595–607.

    Article  PubMed  CAS  Google Scholar 

  63. El-Taji O, Taktak S, Jones C, Brown M, Clarke N, Sachdeva A. Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2024;10:874–84.

  64. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.

    Article  PubMed  CAS  Google Scholar 

  65. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66:815–25.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151–4.

    Article  PubMed  CAS  Google Scholar 

  67. Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with Enzalutamide in prostate cancer after chemotherapy. N. Engl J Med. 2012;367:1187–97.

    Article  PubMed  CAS  Google Scholar 

  68. Lee HY, Chen H-L, Teoh JY-C, Chen T-C, Hao S-Y, Tsai H-Y, et al. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. Prostate Cancer Prostatic Dis. 2021;24:244–52.

    Article  PubMed  CAS  Google Scholar 

  69. Hu J, Aprikian AG, Vanhuyse M, Dragomir A. Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data. Clin Genitourin Cancer. 2022;20:17–24.

    Article  PubMed  Google Scholar 

  70. Pia A, Vignani F, Attard G, Tucci M, Bironzo P, Scagliotti G, et al. Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treat Rev. 2013;39:966–73.

    Article  PubMed  CAS  Google Scholar 

  71. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl J Med. 2004;351:1513–20.

    Article  PubMed  CAS  Google Scholar 

  72. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for advanced prostate cancer. N. Engl J Med. 2004;351:1502–12.

    Article  PubMed  CAS  Google Scholar 

  73. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl J Med. 2015;373:737–46.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30:1992–2003.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl J Med. 2020;382:2091–102.

    Article  PubMed  Google Scholar 

  77. Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094–108.

    Article  PubMed  CAS  Google Scholar 

  78. Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26:2487–96.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada

    Joseph Moryousef, Wilhelmina Duivenvoorden & Jehonathan H. Pinthus

  2. The Research Institute of St. Joe’s Hamilton, Hamilton, ON, Canada

    Wilhelmina Duivenvoorden & Jehonathan H. Pinthus

  3. Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada

    Darryl Leong

Authors
  1. Joseph Moryousef
    View author publications

    Search author on:PubMed Google Scholar

  2. Wilhelmina Duivenvoorden
    View author publications

    Search author on:PubMed Google Scholar

  3. Darryl Leong
    View author publications

    Search author on:PubMed Google Scholar

  4. Jehonathan H. Pinthus
    View author publications

    Search author on:PubMed Google Scholar

Contributions

Conception and design: JM, JHP. Data acquisition: JM, WD, JHP Writing: all authors. Critical Revision: WD, DL, JP. Supervision: JP.

Corresponding author

Correspondence to Jehonathan H. Pinthus.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics statement

We did not seek institutional Review Board Approval as this was a narrative review paper and data was synthesized from existing literature.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moryousef, J., Duivenvoorden, W., Leong, D. et al. Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies. Prostate Cancer Prostatic Dis 28, 632–638 (2025). https://doi.org/10.1038/s41391-024-00897-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41391-024-00897-x

This article is cited by

Search

Advanced search

Quick links